APA (7th ed.) Citation

Rajwa, P., Quhal, F., Pradere, B., Gandaglia, G., Ploussard, G., Leapman, M. S., . . . Shariat, S. F. (2023). Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature reviews. Urology, 20(4), 205-216. https://doi.org/10.1038/s41585-022-00680-4

Chicago Style (17th ed.) Citation

Rajwa, Pawel, et al. "Prostate Cancer Risk, Screening and Management in Patients with Germline BRCA1/2 Mutations." Nature Reviews. Urology 20, no. 4 (2023): 205-216. https://doi.org/10.1038/s41585-022-00680-4.

MLA (9th ed.) Citation

Rajwa, Pawel, et al. "Prostate Cancer Risk, Screening and Management in Patients with Germline BRCA1/2 Mutations." Nature Reviews. Urology, vol. 20, no. 4, 2023, pp. 205-216, https://doi.org/10.1038/s41585-022-00680-4.